<H1>Chapter DOI: 10.1208/aapsj070351<br/>Cited-By Count: 70</H1><table border="1" width="30%"><tr><td>Total References</td><td>21</td></tr><tr><td>Springer references</td><td>4</td></tr><tr><td>Non Springer references</td><td>17</td></tr><tr><td>BibStructured Count</td><td width="10%">12</td></tr><tr><td>BibUnstructured Count</td><td width="10%">9</td></tr><tr><td>DOI already available in SpringerLink</td><td>9</td></tr><tr><td>Additional DOI extracted from CrossRef-Meta</td><td>0</td></tr><tr><td>Additional DOI extracted from CrossRef-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from ResearchGate-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from SpringerLink-FUZZY-Search</td><td>0</td></tr><tr><td>Spelling Mistakes</td><td>NULL</td></tr><tr><td>Wrong DOI</td><td>0</td></tr><tr><td>ISBN</td><td>NULL</td></tr><tr><td>Web Link</td><td>NULL</td></tr><tr><td>DOI Obtained For Springer Published</td><td>0</td></tr><tr><td>DOI Obtained For Non Springer</td><td>0</td></tr><tr><td>DOI Obtained From Structured Ref</td><td>0</td></tr><tr><td>DOI Obtained From Unstructured Ref</td><td>0</td></tr><tr><td>Valid DOI Enriched</td><td>0</td></tr></table></br></br><table border="1">
<tr><th>Bib. ID</th><th>Ref. Type</th><th>References</th><th>DOI</th><th>Suspected DOI</th><th>DOI Source</th><th>Validated Elements</th><th>Validation Source</th></tr><tr><td>CR1</td><td>BibArticle</td><td>Olson SC, Bockbrader H, Boyd RA, et al. Impact of population pharmacokinetic-pharmacodynamic analyses on the drug development process: experience at Parke-Davis.<Emphasis Type="Italic">Clin Pharmacokinet</Emphasis>. 2000;38:449&#8211;459.</td><td><a href=http://dx.doi.org/10.2165/00003088-200038050-00005>10.2165/00003088-200038050-00005</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR2</td><td>BibArticle</td><td>Reigner BG, Williams PE, Patel IH, Steimer JL, Peck C, van Brummelen P. An evaluation of the integration of pharmacokinetic and pharmacodynamic principles in clinical drug development. Experience within Hoffmann La Roche.<Emphasis Type="Italic">Clin Pharmacokinet</Emphasis>. 1997;33:142&#8211;152.</td><td><a href=http://dx.doi.org/10.2165/00003088-199733020-00005>10.2165/00003088-199733020-00005</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR3</td><td>BibChapter</td><td>Ette EI, Miller R, Gillespie WR, et al. The Population Approach: FDA Experience. In Balant LP and Aarons L, eds.<Emphasis Type="Italic">The Population Approach: Measuring and Managing Variability in Response, Concentration and Dose</Emphasis>. Commission of the European Communities, European Cooperation in the Field of Scientific and Technical Research, Brussels, 1997.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR4</td><td>BibArticle</td><td>Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group.<Emphasis Type="Italic">N Engl J Med</Emphasis>. 2000;343:246&#8211;253.</td><td><a href=http://dx.doi.org/10.1056/NEJM200007273430403>10.1056/NEJM200007273430403</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR5</td><td>BibUnstructured</td><td><span style='background:#BDBAD6'>Nesiritide.</span> Center for Drug Evaluation and Research, United States Food and Drug Administration. Available at: <span style='background:#FF3300'>http://www.fda.gov/ohrms/dockets/ac/cder99t.htm#Cardiovascular%20and%</span> 20Renal%20Drugs/3490t2.pdf. Accessed on March 21, <span style='background:#66FF66'>2005</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR6</td><td>BibArticle</td><td>Publication Committee for the VMAC Investigators. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial.<Emphasis Type="Italic">JAMA</Emphasis>. 2002;287:1531&#8211;1540.</td><td><a href=http://dx.doi.org/10.1001/jama.287.12.1531>10.1001/jama.287.12.1531</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR7</td><td>BibUnstructured</td><td><span style='background:#BDBAD6'>Apomorphine</span>, <span style='background:#FFD9B3'>Center for Drug Evaluation and Research, US Food and Drug Administration</span>. <span style='background:#FFFF0F'>Available at: http://www.fda.gov/cder/foi/nda/2004/21-264_Apokyn.htm Accessed on March 21, 2005</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR8</td><td>BibArticle</td><td>Chang JT, Green L, Beitz J. Renal failure with the use of zoledronic acid.<Emphasis Type="Italic">N Engl J Med</Emphasis>. 2003;349:1676&#8211;1679.</td><td><a href=http://dx.doi.org/10.1056/NEJM200310233491721>10.1056/NEJM200310233491721</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR9</td><td>BibArticle</td><td>Booth B, Rahman A, Ibrahim A, et al. A population pharmacokinetic model for zoledronic acid (ZOMETA) in patients with bone metastases.<Emphasis Type="Italic">Am Soc Clin Pharmacol Ther</Emphasis>. 2003;(PIII&#8211;20):67.</td><td><a href=http://dx.doi.org/10.1016/S0009-9236(03)90605-9>10.1016/S0009-9236(03)90605-9</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR10</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#DDDDDD'>Zoledronic Acid</span> <span style='background:#BCBCBC'>Label</span></span></aug>: <span style='background:#FFD9B3'>Center for Drug Evaluation and Research, US Food and Drug Administration</span>. Available at: <span style='background:#FF3300'>www.fda.gov/cder/foi/label/2005/021223s009.0101bl.pdf</span>. Accessed March 21, <span style='background:#66FF66'>2005</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR11</td><td>BibUnstructured</td><td><span style='background:#BDBAD6'>Zometa (Zoledronic Acid)</span>: <span style='background:#FFD9B3'>Center for Drug Evaluation and Research, US, Food and Drug Administration</span>. Available at: <span style='background:#FF3300'>http://www.fda/gov/medwatch/SAFETY/2005/safety05.htm#Zometa</span>. Accessed March 29, <span style='background:#66FF66'>2005</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR12</td><td>BibUnstructured</td><td><span style='background:#BDBAD6'>Busulfan, Center for Drug Evaluation and Research</span>, <span style='background:#FFD9B3'>United States Food and Drug Administration</span>. Available at: <span style='background:#FF3300'>http://www.fda.gov/cder/foi/nda/2002/20-954S004_Busulfex.htm</span> Accessed March 21, <span style='background:#66FF66'>2005</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR13</td><td>BibArticle</td><td>Slattery JT, Clift RA, Buckner CD, et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation.<Emphasis Type="Italic">Blood</Emphasis>. 1997;89:3055&#8211;3060.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR14</td><td>BibArticle</td><td>Grochow LB, Jones RJ, Brundrett RB, et al. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation.<Emphasis Type="Italic">Cancer Chemother Pharmacol</Emphasis> 1989;25:55&#8211;61.</td><td><a href=http://dx.doi.org/10.1007/BF00694339>10.1007/BF00694339</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR15</td><td>BibArticle</td><td>DeMagalhaes-Silverman M, Bloom EJ, Donnenberg A, et al. Toxicity of busulfan and cyclophosphamide (BU/CY2) in patients with hematologic malignancies.<Emphasis Type="Italic">Bone Marrow Transplant</Emphasis>. 1996;17:329&#8211;333.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR16</td><td>BibUnstructured</td><td><span style='background:#BDBAD6'><span style='background:#BDBAD6'>Betapace (Sotalol Hydrochloride)</span>.</span> Center for Drug Evaluation and Research, United States Food and Drug Administration. Available at:http://www.fda.gov/cder/foi/nda/2001/19-865s10_Betapace.htm. Accessed March 21, <span style='background:#66FF66'>2005</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR17</td><td>BibArticle</td><td>Shi J, Ludden TM, Melikian AP, Gastonguay MR, Hinderling PH. Population pharmacokinetics and pharmacodynamics of sotalol in pediatric patients with supraventricular or ventricular tachyarrhythmia.<Emphasis Type="Italic">J Pharmacokinet Pharmacodyn</Emphasis>. 2001;28:555&#8211;575.</td><td><a href=http://dx.doi.org/10.1023/A:1014412521191>10.1023/A:1014412521191</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR18</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Gobburu</span> <span style='background:#DDDDDD'>J.</span></span></aug> Could an, EOP2A meeting shorten drug development time? Available at: <span style='background:#FF3300'>http://www.fda.gov/ohrms/dockets/ac/03/slides/3998S1_06_Gobburu_files/frame.htm</span>. Accessed March 21, <span style='background:#66FF66'>2005</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR19</td><td>BibArticle</td><td>Kola I, Landis J. Can the pharmaceutical industry reduce, attrition rates?<Emphasis Type="Italic">Nat Rev Drug Discov</Emphasis>. 2004;3:711&#8211;715.</td><td><a href=http://dx.doi.org/10.1038/nrd1470>10.1038/nrd1470</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR20</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#DDDDDD'>Advisory Committee for Pharmaceutical</span> <span style='background:#BCBCBC'>Science</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#DDDDDD'>Clinical Pharmacology</span> <span style='background:#BCBCBC'>Subcommittee</span></span></aug>, <span style='background:#FFD9B3'>US Food and Drug Administration</span>. Available at: <span style='background:#FF3300'>http://www.fda.gov/ohrms/dockets/ac/03/slides/</span> 3998s1.htm. Accessed March 29, <span style='background:#66FF66'>2005</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR21</td><td>BibUnstructured</td><td><span style='background:#BDBAD6'>Challenge and Oppurtunity on the Critical Path to New Medical Products</span>, <span style='background:#FFD9B3'>United States Food and Drug Administration</span>. Available at: <span style='background:#FF3300'>http://www.fda.gov/oc/initiatives/criticalpath/</span>. Accessed March 21, <span style='background:#66FF66'>2005</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></table>